LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

计划入组 12 人 · 首次发布于 2024 年 1 月 10 日

Neovascular Age-related Macular Degeneration

计划入组 44 人 · 首次发布于 2012 年 10 月 23 日

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

计划入组 295 人 · 首次发布于 2020 年 2 月 11 日

Brolucizumab(Beovu)

FOV-RD27

LYN-002

Optiva Inc

Australia

Ocugen

United States

NEW AGE VENTURES LLC

United States

Faricimab Demonstrates Efficacy in Treatment-Naïve Neovascular AMD Patients

ABBV-RGX-314 Gene Therapy Shows Promise in Bilateral Neovascular AMD

Merck Initiates Pivotal Phase 2b/3 Trial for Novel Bispecific Antibody MK-8748 in Wet Age-Related Macular Degeneration